Brainsway (NASDAQ:BWAY) Stock Rating Upgraded by Wall Street Zen

Key Points

• Brainsway has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting positive investor sentiment.
• The company reported $0.10 earnings per share, surpassing analyst expectations of $0.07, indicating strong quarterly performance.
• Shares of Brainsway opened at $12.98 on Friday, with a recent 52-week high of $13.65, suggesting strong market interest and growth potential.

Brainsway (NASDAQ:BWAY - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday.

A number of other analysts have also commented on BWAY. HC Wainwright lifted their target price on shares of Brainsway from $16.00 to $17.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Northland Securities lifted their target price on shares of Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a report on Thursday, August 14th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Brainsway currently has a consensus rating of "Buy" and an average price target of $18.00.

Brainsway Trading Up 0.7%

Shares of Brainsway stock traded up $0.10 during midday trading on Friday, reaching $14.57. The company had a trading volume of 36,786 shares, compared to its average volume of 53,876. The company has a market capitalization of $275.37 million, a price-to-earnings ratio of 56.04 and a beta of 1.42. The stock has a fifty day simple moving average of $12.21 and a 200 day simple moving average of $10.59. Brainsway has a 1-year low of $7.06 and a 1-year high of $15.00.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.03. The business had revenue of $12.63 million during the quarter, compared to analyst estimates of $12.34 million. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. Brainsway has set its FY 2025 guidance at EPS. Sell-side analysts expect that Brainsway will post 0.08 earnings per share for the current year.

Institutional Investors Weigh In On Brainsway

Institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC bought a new stake in Brainsway in the 4th quarter valued at $44,000. Raymond James Financial Inc. bought a new stake in Brainsway in the 2nd quarter valued at $85,000. GAMMA Investing LLC lifted its position in Brainsway by 720.7% in the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after acquiring an additional 8,216 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in Brainsway in the 1st quarter valued at $111,000. Finally, Trexquant Investment LP acquired a new stake in Brainsway in the 1st quarter valued at $129,000. 30.11% of the stock is owned by institutional investors.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.